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Table 1 Patients performance status
Colorectal cancer (CRC) accounts for approximately 300,0000 deaths worldwide every year. Approximately 20% of newly diagnosed CRC is metastatic at the time of initial presentation, and more than 50% of patients with early-stage CRC at initial diagnosis will eventually present with metastatic disease. In metastatic CRC (mCRC), 5-year survival is only 6% worldwide. For decades fluoropyrimidines formed the backbone of treatment in mCRC [1, 2] . The relatively recent introduction of oxaliplatin, irinotecan and biologic therapies (bevacizumab, panitumumab, cetuximab and aflibercept) allowed to reach the median overall survival of 23-24 months and up today monoclonal antibodies combined with standard chemotherapy are recommended for management of mCRC. But the improvement in survival for mCRC patient led to a significant number of patients progressing beyond the second or third line of treatment still suitable for further therapy [3] . Unfortunately, few options are available in the third-line setting and it is clear that there is a need for new and effective drugs and treatment regimens. More recently, the multikinaseinhibitor of VEGFR2 and TIE2, regorafenib has been approved in patients not considered candidates for available therapies [4, 5] .
The objective of this study was to assess the oncologists' real clinical practice in the management of mCRC patients, with a focus on the 3rd, 4th and later lines of therapy in Italy. About 40% of molecules administered in 3rd line and 67% of molecules administered in 4th line had already been used in previous lines.
The mean cost for a 3rd line patient was € 11,020 whereas the mean cost for a 4th line patient was € 7,248 (Figure 1 ). Table 2 . Therapeutic schema administered in 3 rd line therapy 
Therapeutic schema N° of patients %

